医学
佐剂
辅助治疗
肿瘤科
内科学
免疫系统
全身疗法
多元分析
阶段(地层学)
单变量分析
乳腺癌
癌症
免疫学
生物
古生物学
作者
Rishu Takimoto,Takashi Kamigaki,SACHIKO OKADA,HIROSHI IBE,ERI OGUMA,Shigenori Goto
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2022-07-26
卷期号:42 (8): 4179-4187
被引量:1
标识
DOI:10.21873/anticanres.15918
摘要
The efficacy of adjuvant systemic therapy after surgical resection remains unsatisfactory; therefore, a new treatment strategy is required. We aimed to examine the efficacy of adjuvant immune-cell therapy using activated T lymphocytes with or without dendritic cell vaccination in combination with standard adjuvant systemic therapies in terms of the survival of patients with solid tumors, such as lung, gastric, pancreatic, colorectal, and breast cancers.A total of 141 patients with solid tumors were enrolled in this study. The correlation of overall survival and disease-free survival with various clinical factors such as age, sex, performance status score, clinical stage, treatment strategies, and vital status was investigated by univariate and multivariate analyses.Multivariate analysis revealed that a performance status score of 0 was a favorable prognostic factor in the full analysis set of solid tumors (HR=0.209, 95%CI=0.065-0.676, p=0.0089) and might be the indication for immune-cell therapy in the adjuvant setting.Adjuvant immune-cell therapy combined with other systemic therapies would potentially provide a survival benefit in patients with solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI